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Summary
Immunity against Theileria parva is associated with CD8 T-cell responses
that exhibit immunodominance, focusing the response against limited
numbers of epitopes. As candidates for inclusion in vaccines, characteriza-
tion of responses against immunodominant epitopes is a key component
in novel vaccine development. We have previously demonstrated that the
Tp249–59 and Tp1214–224 epitopes dominate CD8 T-cell responses in BoLA-
A10 and BoLA-18 MHC I homozygous animals, respectively. In this
study, peptide–MHC I tetramers for these epitopes, and a subdominant
BoLA-A10-restricted epitope (Tp298–106), were generated to facilitate accu-
rate and rapid enumeration of epitope-specific CD8 T cells. During valida-
tion of these tetramers a substantial proportion of Tp249–59-reactive T
cells failed to bind the tetramer, suggesting that this population was
heterogeneous with respect to the recognized epitope. We demonstrate
that Tp250–59 represents a distinct epitope and that tetramers produced
with Tp50–59 and Tp49–59 show no cross-reactivity. The Tp249–59 and
Tp250–59 epitopes use different serine residues as the N-terminal anchor
for binding to the presenting MHC I molecule. Molecular dynamic mod-
elling predicts that the two peptide–MHC I complexes adopt structurally
different conformations and Tcell receptor b sequence analysis showed
that Tp249–59 and Tp250–59 are recognized by non-overlapping T-cell
receptor repertoires. Together these data demonstrate that although differ-
ing by only a single residue, Tp249–59 and Tp250–59 epitopes form distinct
ligands for T-cell receptor recognition. Tetramer analysis of T. parva-spe-
cific CD8 T-cell lines confirmed the immunodominance of Tp1214–224 in
BoLA-A18 animals and showed in BoLA-A10 animals that the Tp249–59
epitope response was generally more dominant than the Tp250–59 response
and confirmed that the Tp298–106 response was subdominant.
Keywords: cattle; CD8 T cell; epitope; tetramer; Theileria parva.
Introduction
CD8 T cells play a key role in immunity against a range
of intracellular pathogens. The antigenic specificity of
individual T cells is determined by clonally distributed T-
cell receptors (TCR) that recognize short pathogen-
derived peptide fragments (generally 8–12 amino acids in
length) presented in the context of the host’s MHC class
I (MHC I) molecules on the surface of infected cells.
Although the proteome of most pathogens will contain a
multitude of peptides that have the potential to act as
MHC I-associated epitopes, the CD8 T-cell response
tends to be focused on a limited number of dominant
epitopes. Due to their inherent immunogenicity, such
‘immunodominant’ epitopes are considered to be good
candidates for inclusion in subunit vaccines and, as such,
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identification and characterization of the immune
responses against these epitopes is a critical component of
vaccine development.
Mature MHC I proteins are hetero-trimeric complexes,
composed of a peptide bound to a highly polymorphic
MHC I a heavy chain, non-covalently associated with
invariant b2-microglobulin. In vivo assembly of the pep-
tide–MHC I (pMHC I) is a complex and multi-staged
process that is tightly regulated by a number of chaper-
ones. The repertoire of peptides that can bind to any
MHC I is constrained, first by the dimensions of the pep-
tide-binding groove, which is closed at both ends, so lim-
iting the size of the peptide fragments, and second by the
presence of ‘pockets’ within the groove that preferentially
accommodate certain amino acids at particular positions
in the peptide. Sequence polymorphisms between MHC I
molecules result in morphologically distinct ‘pockets’ and
consequently variation of the repertoire of peptides that
can bind stably. For each MHC I allele, the majority of
peptides that have the capacity to bind share a ‘peptide
motif’, which reflects preferential usage of certain amino
acids in residues involved in ‘anchoring’ the peptide to
the MHC I molecule.
East Coast Fever is an economically important disease
of cattle caused by the tick-borne protozoan parasite
Theileria parva, which is prevalent in large areas of east-
ern and southern sub-Saharan Africa. East Coast Fever is
estimated to kill over 1 million animals per year and is a
major socio-economic constraint on the livelihoods of
pastoralists in the affected regions. Although East Coast
Fever is often lethal, cattle that recover naturally, or are
immunized by an ‘infection and treatment method’ of
vaccination, develop long-lasting strain-specific immu-
nity.1 Immune animals exhibit potent CD8 T-cell
responses specific for lymphocytes infected with the sch-
izont stage of the parasite and there is strong evidence
that these CD8 T cells play a key role in immunity.2–6
The identification of a number of antigens and epitopes
recognized by parasite-specific CD8 T cells in animals of
defined MHC I genotypes has facilitated studies of the
fine antigenic specificity of these responses.7,8 Using
in vitro cytotoxicity assays to analyse large sets of CD8 T-
cell clones, we have demonstrated that two of these epi-
topes – Tp1212–224 and Tp249–59 – are highly immun-
odominant, accounting for > 60% of the CD8 T-cell
response, in animals homozygous for BoLA-A10 (A10)
and BoLA-A18 (A18) MHC I haplotypes, respectively.9
The advent of pMHC I tetramer reagents, composed of
fluorescently labelled tetrameric complexes of recombi-
nant MHC I proteins loaded with defined peptides,10 has
provided a more rapid and precise method for identify-
ing, quantifying and characterizing epitope-specific T
cells, which is independent of the functional properties of
the cells. Herein, we describe studies using pMHC I tetra-
mers to quantify the CD8 T cells specific for three
T. parva epitopes in the Tp1 and Tp2 antigens – Tp1212–
224, Tp249–59 and Tp298–106 – in both in vitro cultured
CD8 T-cell lines and ex vivo T-cell populations. During
these studies we demonstrate that the previously defined
Tp249–59-specific T-cell response in A10 animals is com-
posed of two distinct populations specific for Tp249–59
and Tp250–59. These two epitopes use alternative N-term-
inal serine residues (S50 and S51, respectively) to bind to
the presenting MHC I molecule (2*1201); molecular
dynamics simulations indicate that as a result of this the
Tp249–59 and Tp250–59 peptides assume distinct conforma-
tions when bound to 2*1201, leading to differential TCR
recognition and CD8 T cells with distinct specificities for
either Tp249–59 or Tp250–59.
Materials and methods
Animals, immunization and challenge
Holstein Friesian cattle homozygous for either the A10 or
A18 MHC I haplotypes were selected for the study by a
combination of serological typing with MHC I-specific
monoclonal antibodies11 and MHC I allele-specific
PCR.12 Cattle were immunized against the Muguga stock
of T. parva by infection with cryopreserved sporozoites
and simultaneous administration of a long-acting formu-
lation of oxytetracycline, as described previously.1 Some
of the animals were challenged with a lethal dose of
sporozoites at specified time periods after immunization.
All experimental animal work was completed in accor-
dance with the UK Animals (Scientific Procedures) Act
1986.
Generation of T. parva-specific CD8 T-cell lines and
clones
Theileria parva-specific CD8 T-cell lines were generated as
described previously.13 In brief, peripheral blood
mononuclear cells (PBMC) harvested from immunized
animals by density gradient centrifugation were stimu-
lated three times at weekly intervals by co-culture with c-
irradiated (60 Gy) autologous T. parva-infected cells.
Before the third stimulation, cell lines were depleted of
CD4 T cells and cd T cells by complement-mediated lysis
with lineage-specific antibodies (CD4: IL-A12, IgG2a,14
and TCR-cd: GB21A, IgG2b, VMRD, Washington State
University, WA). During the third stimulation, the cul-
ture medium was supplemented with 100 U/ml of recom-
binant human interleukin-2 (IL-2; Chiron, Emeryville,
CA). Clones were generated from the CD8 T-cell-
enriched cell lines by limiting dilution 7 days after the
third stimulation and expanded by re-stimulation as
detailed elsewhere.13 All tissue culture was conducted in
RPMI-1640 medium supplemented with 10% (v/v) fetal
bovine serum (FBS), 20 mM HEPES buffer, 50 lM b-
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mercaptoethanol, 2 mM L-glutamine, 100 U/ml penicillin
and 100 lg/ml streptomycin.
Purified populations of CD8 T cells specific for Tp249–
59 and Tp250–59 used for TCR-b (TRB) chain sequence
analysis were derived from CD8 T cells purified from
PBMC of immunized animals by MACS separation (Mil-
tentyi Biotec, Bisley, UK) using a CD8-specific mono-
clonal antibody (IL-A51–IgG115), and cultured for 10–
11 days in the presence of autologous T. parva-infected
cells. Epitope-specific T cells were purified from these cul-
tures by tetramer staining followed by cell sorting as
described below and then re-stimulated for an additional
7 days. Purity of tetramer-sorted populations was verified
as being > 98% before mRNA extraction.
Tetramer production
The cDNA clones of the BoLA class I alleles 2*01201 and
6*01301 were used as templates to amplify by PCR the
sequence coding for the extracellular domain (amino acids
G22-P307) of the heavy chains. The PCR products were
cloned into a derivative of plasmid pET3D (Novagen,
Merck, Nottingham, UK) containing a BirA biotinylation
site in-frame with the 30 end of the heavy chain sequences.
The sequence coding for the mature bovine b2-microglo-
bulin (amino acids I21-L118) was cloned into a derivative
of pET9 (Novagen). The proteins were expressed in Escher-
ichia coli BL21 (DE3) as inclusion bodies. The cell cultures
were lysed by high-pressure cell disruption, inclusion bod-
ies collected by centrifugation and washed extensively with
50 mM Tris–HCl, 100 mM NaCl, 1 mM EDTA, 1 mM
dithiothreitol, and 05% (w/v) sodium deoxycholate
(pH 8). Washed inclusion bodies were solubilized, for the
heavy chains, in 6 M guanidine hydrochloride, 100 mM
Tris–HCl (pH 8), and for the b2-microglobulin, in 8 M
urea, 25 mM sodium acetate (pH 4).
Recombinant MHC I/peptide complexes were folded by
direct dilution of the denatured heavy chain (1 lM), b2-
microglobulin (2 lM) and the peptide (10 lM) in the fol-
lowing refolding mixture: 50 mM Tris–HCl, 400 mM L-argi-
nine hydrochloride, 2 mM EDTA, 5 mM reduced
glutathione, 05 mM oxidized glutathione and 01 mM PMSF
(pH85). The mixture was incubated for 72 hr at 4° and
then concentrated by ultrafiltration. The soluble MHC/pep-
tide complexes were purified by gel filtration and biotiny-
lated using the BirA enzyme (Avidity LCC, Denver, CO).
Fluorescent multimers were obtained by mixing biotinylated
MHC/peptide complexes with streptavidin–phycoerythrin
conjugate (BD Pharmingen, Franklin Lakes, NJ).
Tetramer staining and purification of tetramer-positive cells
Tetramer-positive populations within PBMC were anal-
ysed using multi-colour flow cytometry. In brief, PBMC
(1 9 107/ml) were stained with phycoerythrin-labelled
tetramers at a final concentration of 20 nM for 30 min at
room temperature, washed twice in PBS containing 05%
FBS before staining with a mixture of monoclonal anti-
bodies against CD4 (IL-A12), TCR-cd (GB21A), CD21
(CC21, IgG116), NKp46 (EC1.1 IgG117) and CD172a (IL-
A24, IgG118) for 30 min at 4°. After three washes, cells
were incubated for 30 min at 4° with Alexa Fluor 647-
conjugated goat anti-mouse IgG (Life Technologies, Pais-
ley, UK), washed three times, and then SYTOX Red Dead
Cell Stain (Life Technologies) was added. Flow cytometric
analysis was then conducted on a FACSCalibur or cell-
sorting on a FACSAria (both BD Biosciences, Oxford,
UK). All monoclonal antibodies had been titrated to
determine optimal dilutions before the experiment and
the combination of antibodies and stains had been
demonstrated to leave viable CD8 ab T cells as the only
unstained population (data not shown), which could
therefore be gated as the Alexfluor647/SYTOX Red-nega-
tive subset. For tetramer staining of cultured CD8 T cells
staining with lineage-specific antibodies was excluded.
Cytotoxicity and MHC I-binding competition assays
Standard 4-hr [111In]-release cytotoxicity assays were used
to examine the epitope-specificity of CD8 T-cell clones,
using autologous Theileria annulata-infected cells that
had been incubated with peptides (100 ng/ml) for 1 hr
before the assay as target cells. All assays were conducted
in duplicate, and controls included Theileria annulata-
infected target cells without added peptide. Percentage
specific-lysis was calculated as: [(sample release – sponta-
neous release) 9 100%/(maximal release – spontaneous
release)] and expressed as the mean of the duplicated
assays. Maximal and spontaneous release were derived
from triplicates of target cells incubated with 02% (v/v)
Tween-20 and RPMI-1640 medium containing 5% (v/v)
FBS, respectively. All peptides in this study were supplied
by Pepscan Systems (Lelystad, the Netherlands).
The capacity of variants of the Tp249–59 and Tp250–59
peptides to bind MHC I was determined by their ability to
compete with Tp298–106, another epitope also presented by
the 2*01201 MHC I allele.7 Autologous T. annulata-
infected target cells were pre-incubated with individual
peptides at serial threefold dilutions ranging either from
3 lg/ml to 30 ng/ml or from 5 lg/ml to 10 ng/ml for 1 hr
before the addition of Tp298–106 at 100 ng/ml, so that the
competitor/target peptide ratio ranged from either 30 : 1
to 03 : 1 or 50 : 1 to 01 : 1 respectively. After incubation
for a further hour, 4 hr [111In]-release cytotoxicity assays
were performed using a Tp298–106-specific CD8 T-cell clone
at an effector to target ratio of 10 : 1. The MHC-binding
capacity of the Tp249–59 and Tp250–59 peptide variants was
reflected in the inhibition of cytotoxicity as a consequence
of competitive blocking of MHC binding and presentation
of the Tp298–106 peptide.
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TRB chain sequencing
For sequencing of TRB chains expressed by CD8 T-cell
clones, total RNA was extracted using Tri-reagent
(Sigma-Aldrich, Poole, UK) and cDNA synthesized using
the Reverse Transcription System (Promega, Madison,
WI) with priming by the Oligo (dT)15 primer, according
to the manufacturer’s instructions. TRB chains were PCR
amplified using either Vb-subgroup-specific or pan-Vb
primers as described previously19,20 and the products
were sequenced. For sequencing of tetramer-sorted poly-
clonal populations TRB chains were amplified using a
SMART PCR protocol, modified from that described in
Quigley et al.,21 that allows unbiased TRB chain sequenc-
ing. In brief, mRNA was extracted from tetramer-sorted
CD8 T cells using Oligotex Direct mRNA kit (Qiagen,
Manchester, UK) and cDNA was synthesized with the
SMARTer RACE cDNA Kit (Clontech, Paris, France). The
cDNA was then cleaned using NucleoSpin Extract II
(Clontech) before PCR amplification with a bovine TRB
constant gene-specific primer (50-GGA-
GATCTCTGCTTCCGAGGGTTC-30). PCR products were
subjected to agarose gel electrophoresis and extracted,
purified using NucleoSpin Extract II, ligated into pGEM-
T Easy (Promega) and sub-cloned into JM109 E. coli. The
inserts in individual colonies were PCR amplified and the
products were sequenced. Sequence analysis was per-
formed using the DNASIS MAX v2.0 software package under
default conditions (Miriabio, Alameda, CA). Throughout
the manuscript, nomenclature based on the World Health
Organization-IUIS TCR nomenclature system as used by
Arden et al.22 has been employed for Vb genes, whereas
the Jb gene nomenclature is based upon their organiza-
tion in the bovine TRB locus.23
Molecular dynamics simulations
The coordinates for the bovine MHC class I allele
6*01301 bound to both b2-microglobulin and to the 11-
mer peptide from T. parva, Tp1214–224 were obtained
(pdb code 2XFX24). By using the DEEPVIEW Swiss PDB
Viewer, the sequence of MHC I allele 2*1201 was
threaded into the structure of the 6*01301 allele and the
sequence of the Tp249–59 peptide was threaded into the
structure of the Tp1214–224 peptide; the b2-microglobulin
structure was left unchanged. The new model was energy
minimized in DEEPVIEW and coordinates were saved. A
replicate model with the 10-mer peptide Tp250–59 was
created by removing a central amino acid from the pep-
tide structure, re-ligating the peptide backbone, re-creat-
ing the correct amino acid sequence and then energy
minimizing in DEEPVIEW. This process yielded two start-
ing structures for simulations.
All molecular dynamics simulations were performed by
use of the AMBER 7 suite of programmes and essentially
followed previously published methods for estimating the
structures of peptides bound to MHC molecules.25 In all
simulations the Gibbs approximation of implicit water
was used with a salt concentration of 01 M, a non-
bonded cut-off of 120 A and a step length of 1 fs.
Briefly, structures were extensively energy minimized to
remove local hotspots introduced by the threading/muta-
genesis procedures and were then subjected to a simu-
lated annealing process followed by constant temperature
molecular dynamics at 283 K. During the annealing phase
the temperature was raised to 1500 K over 80 ps, held at
1500 K for a further 80 ps and then reduced to 283 K
over 800 ps before a final hold at 283 K for 40 ps (total
annealing time 1 ns). During the initial energy minimiza-
tion an energy constraint of 5 kcal/mol was applied to
both the MHC I molecule and b2-microglobulin, whereas
during the simulated annealing these restraints were
raised to 20 kcal/mol. Also, during the annealing phase,
three distance constraints were applied to ensure that the
peptide remained in the binding groove – these con-
straints limited hydrogen bond lengths between: (i) OG1
atom of Thr 148 of MHC I and the C-terminal O atom
of the peptide; (ii) OH atom of Tyr 164 of MHC I and
the carbonyl oxygen of peptide residue 1; and (iii) the
OH atom of Tyr 176 of MHC I and the N-terminal N
atom of peptide residue 1. In all simulations the ‘shake’
algorithm was applied to limit bond lengths involving
hydrogen atoms. The final structures after simulated
annealing were energy minimized without restraints and
structures were subjected to 4 ns of molecular dynamics
at 283 K in the presence of the above three distance con-
straints and with 20 kcal/mol positional restraints applied
to the MHC I and b2-microglobulin molecules. Coordi-
nates were saved at regular intervals throughout the
molecular dynamics simulations and analysed using
VMD; VMD is developed with NIH support by the Theo-
retical and Computational Biophysics group at the Beck-
man Institute, University of Illinois at Urbana-
Champaign, USA.26
Results
A subset of Tp249–59 peptide-reactive CD8 T cells do
not bind the Tp249–59/2*01201 tetramer
Previous analyses of panels of cloned CD8 T-cell lines
demonstrated that the responses of A10 and A18
homozygous cattle against T. parva Muguga were domi-
nated by T cells specific for the Tp249–59
(KSSHGMGKVGK) and Tp1214–224 (VGYPKVKEEML)
epitopes respectively.9 In these analyses Tp298–106
(QSLVCVLMK) was found to be a subdominant epitope
in homozygous A10 responses. As part of efforts to
extend our studies to include ex vivo analyses, pMHC I
tetrameric complexes were generated with the relevant
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MHC I heavy chains (6*01301 for Tp1214–224 and
2*01201 for both Tp249–59 and Tp298–106).
In initial experiments to validate these tetramers, epi-
tope-specific CD8 T-cell clones and polyclonal T-cell lines
(from which defined percentages of epitope-specific T-cell
clones had been determined by cytotoxicity assays against
peptide-loaded autologous targets), were stained with the
tetramers (Table 1). The percentage of Tp1214–224-tetra-
mer-positive cells in polyclonal T. parva Muguga-specific
CD8 T-cell lines from two A18 homozygous animals cor-
responded well with results from clonal analysis. Simi-
larly, the percentage of Tp298–106-tetramer-reactive cells in
polyclonal T. parva Muguga-specific CD8 T-cell lines
from two A10 homozygous animals approximated to that
determined by epitope-specific cytotoxicity results. In
contrast, the percentage of Tp249–59-tetramer-positive cells
in the A10 homozygous lines was considerably lower than
that indicated from the clonal analyses of the lines. Exam-
ination of individual CD8 T-cell clones (n = 29) demon-
strated that half of those shown to react with the Tp249–
59 peptide did not stain with the Tp249–59-tetramer
(Table 2). These data suggested that the Tp249–59-specific
populations defined by cytotoxicity assays were in fact
heterogeneous and included a component for which
Tp249–59 was not the epitope.
Tp250–59 is a novel 2*01201-restricted T. parva
epitope
A potential reason for some Tp249–59 peptide-reactive T-
cell clones failing to bind the Tp249–59-tetramer is that
they recognize a truncated version of the Tp249–59 pep-
tide. This could have been missed in the initial minimal
epitope mapping of the Tp249–59 epitope
7 if the
polyclonal CD8 T-cell line used had a low frequency of T
cells specific for a shorter epitope. We therefore per-
formed minimal-length peptide screening with synthetic
peptides using three CD8 T-cell clones that recognized
Tp249–59-pulsed targets but failed to react with the Tp249–
59-tetramer (Fig. 1). For all three clones the N-terminal
truncated 10-mer Tp250–59 (SSHGMGKVGK) was found
to be the preferred epitope (Fig. 1a–c), maintaining the
ability to elicit cytotoxicity at approximately a log lower
peptide concentration (EC50 = 1 9 10
9 to 1 9 1010 M)
than the Tp249–59 11-mer (EC50 = 1 9 10
8 to
1 9 109 M). Recognition of the 9-mer peptide Tp251–59
was substantially weaker, failing to elicit cytotoxicity at
concentrations below 3 9 108 M. Analysis of a Tp249–59-
tetramer-reactive clone demonstrated that, as anticipated,
lysis was observed only with cells incubated with the
Tp249–59 11-mer (Fig. 1d). Removal of one residue at the
C-terminus (Tp249–58 10-mer) resulted in loss of T-cell
recognition by all four clones examined (Fig. 1a–d).
Tp249–59- and Tp250–59-specific CD8 T cells are
distinct populations
Based on these data, a Tp250–59/2*01201 tetramer was
generated and shown to positively stain all CD8 T-cell
clones that recognized Tp249–59-pulsed cells but failed
to react with the Tp249–59-tetramer (Table 2). Con-
versely, those clones that stained with the Tp249–59-tet-
ramer did not stain with the Tp250–59-tetramer,
demonstrating that Tp249–59- and Tp250–59-specificity is
mutually exclusive (e.g. Fig. 2) Furthermore they indi-
cated that the Tp249–59- and Tp250–59-tetramer staining
populations together constitute the total of the previ-
ously defined Tp249–59-specific populations; within the
Table 1. Frequency of epitope-specific populations in polyclonal Theileria parva-specific CD8 T-cell lines from BoLA-A10 and BoLA-18 homozy-
gous animals identified by clonal analysis and peptide–MHC I-tetramer staining
Animal
Immune
status
BoLA-A18
BoLA-A10
Tp1214–224 Tp298–106 Tp249–59
Clonal
analysis Tetramer Clonal analysis Tetramer Clonal analysis
Tp249–59
Tetramer
Tp250–59
Tetramer
Tp249–59 + Tp250–59
Tetramer
592 (A10) PI 3% 35% 60% 238% 200% 438%
PC 10% 116% 80% 322% 325% 647%
1011 (A10) PI 2% 31% 74% 560% 105% 665%
PC 2% 10% 61% 409% 277% 686%
641 (A18) PI 78% 700%
468 (A18) PI 81% 764%
The percentage of epitope-specific T cells in polyclonal T. parva-specific CD8 T-cell lines obtained from BoLA-A10 (592 and 1011) and BoLA-
A18 homozygous animals (641 and 468) as defined by analysis of cytotoxic activity of panels of cloned CD8 T cells against peptide-loaded autol-
ogous targets (clonal analysis) and direct pMHC I tetramer staining. Post-immunization (PI) Post-challenge (PC). IFNG analysis on subsets of
clones indicated that the frequency of epitope-specific (i.e. IFNG+) but non-cytotoxic cells in the lines examined was negligible (data not shown)
and therefore cytotoxicity has been taken as a proxy for epitope-specificity.
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polyclonal lines the combined frequency of the Tp249–
59- and Tp250–59-tetramer stained cells were similar to
that of Tp49–59-specific cells obtained from cytotoxicity
analysis (Table 1).
To further investigate the distinct nature of these popu-
lations, the TCR repertoires of sets of Tp249–59- and
Tp250–59-specific CD8 T cells were examined by sequenc-
ing of the expressed TRB chains. The CD8 T-cell clones
derived from the two A10 animals (592 and 1011) exhib-
ited a broad sequence repertoire although there were
dominant clonotypes present in both animals (Table 2).
The TRB repertoires of the Tp249–59- and Tp250–59-speci-
fic populations were largely ‘private’ (i.e. not shared
between animals); however, there was one TRB sequence
(VB28.1-AEYGGENTQPL-JB3s2) which was shared by a
proportion of the Tp250–59-specific clones of the two ani-
mals. In contrast, there was no evident commonality of
TRB sequences between the Tp249–59- and Tp250–59-speci-
fic populations within the individual animals.
To provide a higher resolution analysis, larger numbers
(> 70) of TRB chains were sequenced from Tp249–59- and
Tp250–59-tetramer-sorted cell lines established from two
additional A10-homozygous animals (302186 and
403992), using a SMART-PCR protocol that allows unbi-
ased TRB chain sequencing in multi-clonal populations.
The Tp249–59- and Tp250–59-specific populations were
oligoclonal, being dominated by one or two large clono-
types, and the TRB repertoires were largely ‘private’
(Fig. 3), although the VB28.1-AEYGGENTQPL-JB3s2
TRB chain observed in animals 592 and 1011 was also
identified in animal 302186. Critically, across the four
animals no TRB sequence was shared between Tp249–59-
and Tp250–59-specific T cells. The disparity between the
TRB chain repertoires of CD8 T cells specific for the two
Table 2. Peptide–MHC I tetramer staining of Theileria parva-specific CD8 T-cell clones derived from BoLA-A10 homozygous animals that cyto-
toxic analysis had identified as Tp249–59-specific
Clone
TRB sequence Tetramer staining
TRBV CDR3 TRBJ Tp249–59 Tp250–59
1011.1-1 1.6 SQVGGIYGEL 3s1  +
592.54-1 1.7 SPNSYEQ 3s7  +
592.56-1 1.7 SPNSYEQ 3s7  +
592.77-1 2.4 QWGGSYEEQ 2S1  +
1011.37-1 2.4 RFGPGGLSYEQ 3S7  +
592.15-1 3.1 SRKGGGLQSTQ 2S3 + 
592.43-1 10.2 SQADSGAYEQ 3S7 + 
592.43-3 12.1 HIRGGLDTQPL 3S2  +
1011.68-3 12.2 SYSPGGGSPL 3S3 + 
1011.12-1 12.2 SYSPGGGSPL 3S3 + 
592.9-1 13.2 SHAGYEQ 3S7 + 
1011.13-1 14.1 SVGNSNYEQ 3s7 + 
1011.21-1 14.1 SVGNSNYEQ 3s7 + 
1011.25-1 14.1 SVGNSNYEQ 3s7 + 
1011.16-3 14.1 SVGNSNYEQ 3s7 + 
1011.22-3 14.1 SVGNSNYEQ 3s7 + 
1011.21-3 14.1 SVGNSNYEQ 3s7 + 
1011.29-3 14.1 SVGNSNYEQ 3s7 + 
1011.31-3 14.1 SVGNSNYEQ 3s7 + 
1011.6-3 28.1 AEYGGENTQPL 3s2  +
1011.15-3 28.1 AEYGGENTQPL 3s2  +
1011.35-3 28.1 AEYGGENTQPL 3s2  +
592.35-1 28.1 AEYGGENTQPL 3s2  +
592.50-1 28.1 AEYGGENTQPL 3s2  +
592.59-1 28.1 AEYGGENTQPL 3s2  +
592.18-1 28.1 AEYGGENTQPL 3s2  +
592.26-1 28.1 AEYGGENTQPL 3s2  +
592.55-1 28.1 GGRDSIYDY 3s2  +
1011.5-1 X SKAAAEDGYEQ 3S7 + 
For each clone the designated name (animal number, clone number and a ‘–1’ and ‘3’ suffix referring to clones derived from lines established
post-immunization and post-challenge respectively), sequence of the expressed TRB chains (composed of the TRBV gene, amino acid sequence of
the CDR3 region and the TRBJ gene) and the result of staining with the Tp249–59 and Tp250–59 pMHC I tetramers are shown.
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epitopes, indicate that they represent biophysically dis-
crete pMHC I ligands for TCR recognition.
Tp249–59 and Tp250–59 epitopes use different N-
terminal MHC I binding anchor residues
In a previous study, alanine scanning mutagenesis
demonstrated that Lys59 was the C-terminus anchor resi-
due of the Tp249–59 epitope but an N-terminal anchor
residue was not identified.27 MHCCLUSTER 2.0 predictions
indicating that a serine (Ser), alanine (Ala) or threonine
(Thr) at P2 is the preferred N-anchor residue for
2*0120128 suggests that single-alanine mutagenesis may
not have affected MHC I binding either as a consequence
of the similar biophysical characteristics of Ser and Ala
(small and neutral) and/or the capacity of the tandem
Ser50 and Ser51 residues to serve as alternative anchor
residues. Further MHC I-binding competition assays
using peptides in which either or both Ser50 and Ser51
residues of both the Tp249–59 (Fig. 4a) and Tp250–59
(Fig. 4b) peptides were substituted with Ala demonstrated
that all permutations of Ser and Ala at these positions
0
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Figure 1. Minimal length peptide screening identifies Tp250–59 as a novel epitope. Cytotoxic activity of Tp49–59-lytic clones against titrated quan-
tities of Tp49–59 and truncations of this peptide. Three clones – 592.11/1 (a), 592.38/1 (b) and 592.57/1 (c) – which lysed Tp49–59-loaded autolo-
gous targets but did not stain with the Tp49–59-tetramer all efficiently lysed Tp50–59- but not Tp51–59 or Tp49–58-loaded targets. 592.78/1 (d) which
stained with the Tp49–59 tetramer lysed Tp49–59-loaded autologous targets but not targets loaded with any of the truncated peptides.
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maintained equivalent capacity to bind 2*01201, indicat-
ing that Ser to Ala substitution was insufficient to disrupt
MHC I binding.
We therefore generated a series of mutant peptides in
which the Ser50 and Ser51 residues were replaced with glu-
tamic acid (Glu – large and negatively charged), leucine
(Leu – large and neutral) and lysine (Lys – large and
positively charged) residues at P2 and evaluated their per-
formance, along with the peptides containing either a P2
serine or alanine substitution, in the MHC I-binding
competition assay (Fig. 4c). Consistent with our previous
observations, the peptides with the Ser or Ala at P2 were
able to bind to 2*01201, but the mutant peptides with
Glu, Leu or Lys residues at P2 all exhibited no or only
very limited binding to 2*01201. Based on these data, we
repeated the MHC I-binding competition assay with posi-
tions 50 and 51 of Tp249–59 and Tp250–59 substituted with
all the different permutations of Ser and Lys. For both
Tp249–59 (Fig. 4d) and Tp250–59 (Fig. 4e) the double
lysine substitutions at positions 50 and 51 (Lys50Lys51)
abrogated MHC I binding, as anticipated. For the Tp249–
59 peptide, the Lys50Ser51 but not the Ser50Lys51 substitu-
tion abrogated MHC I binding, whereas the reciprocal
was true for Tp250–59. These results indicate that Ser50
and Ser51 serve as the N
0 terminal anchors for Tp249–59
and Tp250–59, respectively. A corollary of this is that for
Tp249–59 an extra amino acid has to be accommodated
within the 2*01201 binding groove when compared with
Tp250–59, suggesting that the former must adopt a more
‘bulged’ conformation.
Molecular dynamics simulations of Tp249–59 and
Tp250–59 MHC I complexes predicts different peptide
presentation to TCR
To model the structural differences between the pMHC I
complexes formed by Tp249–59 and Tp250–59 with 2*01201
at the atomic level we adopted a simulated annealing
approach. The predicted structures of the pMHC com-
plexes at the end of the simulated annealing procedure
are shown in Fig. 5. As predicted, when bound to
2*01201 Tp249–59 has a more ‘bulged’ conformation than
Tp250–59, with a greater component of the peptide pro-
truding above the surface of the binding groove. How-
ever, more striking is the overall structural disparity
between the two pMHC I complexes. First, at the N-ter-
minus the side chains of both Lys49 and His52 form
prominent features in the Tp249–59 complex that could
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Figure 3. T-cell receptor-b (TRB) chain sequencing of Tp249–59 and Tp250–59-sorted populations. TRB chains were sequenced from Tp249–59 and
Tp250–59-tetramer sorted populations from 2 BoLA-A10 homozygous animals – (a) 302186 and (b) 403992 – using an unbiased SMART-PCR
protocol. The number of sequences generated from each population was > 70.
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form potential positively-charged recognition sites for
TCR. In contrast, in the model of Tp250–59, Lys49 is obvi-
ously absent and the side-chain of His52 is solvent-pro-
tected, largely because the side chain of residue Arg160 of
the MHC I chain, located on the lip of the binding
groove, overlaps the His52 side-chain. Second, although
the side chains of Met54 and Lys56 in the central region of
the pMHC I structures are surface-exposed in both
Tp249–59 and Tp250–59 and likely to be part of the
pMHC I topography recognized by cognate TCR, the ori-
entation of these two residues is markedly different. We
performed further constant-temperature molecular
dynamics on these structures over 4 ns and analysed pep-
tide conformations over 1 ps. The differences between the
complexes were maintained throughout the simulations,
demonstrating that the conformations depicted in Fig. 5
are representative of the entire data set. Hence, the two
pMHC I complexes are predicted to present different
structural motifs to the TCR, providing the mechanistic
basis for why Tp249–59 and Tp250–59 are recognized by
distinct TCR repertoires and consequently discrete CD8
T-cell populations.
The kinetics and relative immunodominance of Tp2
epitope-specific responses ex vivo
A primary purpose of developing the tetramers was to
facilitate analysis and quantification of epitope-specific
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Figure 4. Tp249–59 and Tp250–59 bind to 2*01201 using different N-terminal anchors. (a and b) An MHC I-binding competition assay in which
all permutations of serine and alanine at Tp250 and Tp251 were analysed demonstrates that the serine to alanine mutation does not abrogate
MHC I binding of either the (a) Tp249–59 or (b) Tp250–59 epitopes, whereas lysine to alanine substitution of Tp259 or removal of S50 does. (c)
Mutant 10-mer peptides in which S50 and S51 are replaced with single alanine (A), serine (S), glutamic acid (E), leucine (L) or lysine (K) residues
demonstrate that the E, L and K substitutions all abrogate MHC I binding. MHC I competition assays in which all permutations of serine and
lysine at Tp250 and Tp251 were analysed demonstrate that S50 and S51 are the N-terminal anchor residues of Tp249–59 (d) and Tp250–59 (e) respec-
tively. In each panel the index peptide (i.e. unmodified or minimally modified) sequence and data are shown in grey.
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CD8 T-cell responses without the need for sustained
in vitro culture and clonal analysis. Two A10 homozygous
animals (403992 and 302186), previously immunized by
the ‘infection and treatment method’ vaccination proto-
col, were challenged with a lethal dose of T. parva sporo-
zoites and the CD8 T-cell responses against Tp249–59,
Tp250–59 and Tp298–106 were monitored directly ex vivo
using tetramers (Fig. 6a,b). In both animals a Tp249–59-
specific response was evident, peaking at day 13/14 post-
challenge at 75% and 05% of CD8 T cells in 302186 and
403992, respectively. A response against Tp250–59 was also
observed in 302186, with a maximum of 028% of tetra-
mer-positive CD8 T cells on day 13 post-challenge (data
not shown). No Tp250–59 response was detected in
403992 and no Tp298–106-tetramer-positive population
was seen in either animal.
To determine if the relative frequency of tetramer-spe-
cific CD8 T cells observed following in vitro stimulation
reflects that observed directly ex vivo, purified CD8 T-cell
cultures were established from these two animals by co-
culture with autologous T. parva-infected cells and anal-
ysed over 13 days (Fig. 6c). Although the enrichment
resulting from the in vitro stimulation enabled the detec-
tion of the subdominant Tp250–59 and Tp298–106 responses
in these cultures, the dominance hierarchy of the Tp249–
59-specific responses corresponded with the results
obtained ex vivo during challenge.
Discussion
Although pMHC I tetramers are widely used in humans
and mice to analyse CD8 T-cell responses, there is only
one report of their use to examine responses in cattle.29
As part of studies to analyse the antigenic specificity of
bovine CD8 T-cell responses to T. parva, the present
study set out to use pMHC I tetramers to quantify CD8
T-cell responses to defined epitopes presented by two
MHC I alleles. In addition to providing data on the rela-
tive abundance of T-cell specificities, both in vivo and
in vitro, the studies revealed that the response to one of
the epitopes comprised two distinct CD8 T-cell popula-
tions specific for 10-mer and 11-mer peptides within the
same 11 amino acid sequence.
All three tetramers examined in the initial experiments
stained discrete populations of cells in polyclonal CD8 T-
cell lines, in which the proportion of epitope-specific T
cells had been estimated previously by clonal analysis
based on detection of cytolysis of peptide-loaded target
cells.9 The percentages of positive cells detected by two of
the tetramers, Tp1214–224/6*01301 and Tp298–106/2*01201,
were consistent with the results obtained using cytotoxic-
ity assays. In contrast, the proportion of Tp249–59/
2*01201 tetramer-positive cells was substantially lower
than expected based on the clonal analysis of the CD8 T-
cell lines and a number of clones shown to recognize the
Tp249–59 peptide failed to stain with the tetramer. Based
on these observations, we tested the ability of three CD8
T-cell clones, which reacted with the Tp249–59 peptide but
were not stained by the tetramer, to recognize a series of
truncated peptides. The results of these experiments
clearly identified Tp250–59 as the minimal epitope for all
three clones. We subsequently showed that all of the
Tp249–59-reactive but Tp249–59/2*01201 tetramer-negative
clones examined stained with a Tp250–59/2*01201 tetra-
mer, demonstrating that Tp249–59 peptide-reactive CD8
T-cell populations were composed of two distinct sub-
populations specific for overlapping epitopes of different
lengths. The failure to identify the Tp250–59 epitope in the
Met54
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Figure 5. Modelling of the Tp249–59 and Tp250–59-2*01201 structures. The conformation of Tp250–59 (a) and (c) and Tp249–59 (b) and (d) after
simulated annealing. (a) and (b) show the peptide structures in isolation, whereas (c) and (d) show the same peptide structures in situ in the
peptide binding groove of 2*01201. In each case, the peptide backbone is displayed as a continuous spline, whereas side chains are displayed as
ball and stick representations. The MHC chain is displayed as a space-filled representation. Figures were prepared using VMD.
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initial epitope mapping studies7 probably reflects the
absence or low frequency of Tp250–59-specific T cells in
the polyclonal CD8 T-cell line used in the analyses.
Recently, another of the identified Tp2 epitopes, restricted
by a different MHC allele, has been shown to be smaller
than initially described.29 Together these data illustrate
how tetramers can be used to verify and refine the epi-
topes identified by traditional epitope mapping tech-
niques.
Few models analogous to the Tp249–59/Tp250–59 over-
lapping epitope scenario have been documented. One
example that has been studied in detail is the HLA-A2-
restricted response against the human melanoma antigen
Melan-AMART-1, where both a nonamer (Melan-A27–
35 – AAGIGILTV) and decamer (Melan-A26–
35 – EAAGIGILTV) are CD8 T-cell epitopes. Crystallo-
graphic studies have shown that the Melan-A27–35 and
Melan-A26–35 epitopes use A28 and A27 residues as the N-
terminal anchors30 for MHC I binding respectively – the
use of alternative tandem residues at the N-terminus
directly imitating the Tp249–59/Tp250–59 scenario. Simi-
larly, the adoption of strikingly different conformations
by Melan-A27–35 and Melan-A26–35 when bound to HLA-
A2 is emulated in the modelling results we present here
for Tp249–59 and Tp250–59. Despite these similarities, there
is a marked difference between the Melan-A27–35/Melan-
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A26–35 and Tp249–59/Tp250–59 systems with regard to tetra-
mer binding. In the Melan-A27–35/Melan-A26–35 system, in
addition to CD8 T-cell subsets specific for either Melan-
A27–35 or Melan-A26–35 there is also a subset that binds
tetramers generated with both peptides.31 Detailed crystal-
lographic analysis of the ternary TCR–pMHC structures
formed by two cross-reactive TCR (DMF4 and DMF5)
with both Melan-A27–35/HLA-A2 and Melan-A26–35/HLA-
A2 have provided insights into the molecular basis of this
cross-reactive capacity of Melan-A-specific T cells.32
Although DMF4 and DMF5 use different mechanisms to
achieve cross-recognition, for both TCRs, a critical com-
mon feature is that upon TCR ligation the nonameric
peptide is lifted out of the MHC I groove and adopts a
‘bulged’ conformation that is more similar to that of the
decamer. This ‘induced molecular mimicry’ has been
described in a variety of pMHC I/TCR structures,33,34
and in the case of Melan-A27–35 the elevation of the pep-
tide may be permitted by the sub-optimal binding of the
A28 residue with the N-terminal pocket of the HLA-A2
(which has a preference for a large residue such as leu-
cine). In contrast, our data indicate that the Tp249–59-
and Tp250–59-tetramers are not cross-reactively bound by
T cells, suggesting that they effectively constitute two sep-
arate pMHC I entities, which are recognized by distinct
repertoires of TCR. TRB chain sequence analysis con-
firmed that Tp249–59- and Tp250–59-specific CD8 T cells
use distinct, non-overlapping TCR repertoires. Molecular
modelling demonstrated that the differences between the
Tp250–59/2*01201 and Tp249–59/2*01201 structures
spanned much of the pMHC I-surface with prominent
N-terminal features in Tp249–59 formed by Lys49 and
His52 being absent from Tp250–59, and different orienta-
tions of the protruding Lys56 residue side chain towards
the C-terminus. Consequently there is limited commonal-
ity between the pMHC I structures available for binding
by cognate TCRs and unlike the Melan-AMART-1 system,
Tp249–59 and Tp250–59 use optimal N-terminal (and C-
terminal) anchors, which may limit the capacity of TCR
binding to alter the conformation of the pMHC I struc-
tures and so reduce the capacity for homogenization by
‘induced molecular’ mechanisms.
The Tp2 antigen is highly polymorphic, showing amino
acid substitutions in 74% of the amino acid residues
among 41 alleles that have been identified to date.35 We
have shown that CD8 T cells directed against the Tp249–
59 and Tp250–59 epitopes are parasite-strain-restricted and
have proposed that the highly dominant nature of
responses to these and other polymorphic epitopes is a
major factor in the failure of different parasite strains to
cross-protect. The ability to generate two distinct
pMHC I ligands from the same peptide sequence for T-
cell recognition, by eliciting separate CD8 T-cell
responses, has the potential to produce greater TCR
diversity than either ligand alone, a feature that has been
proposed to have benefits to host immunity by increasing
the likelihood of cross-reactivity between mutational epi-
tope variants.36–39 However, retrospective analysis of our
previously published data27 demonstrates that Lys56 is
critical for T-cell recognition of both the Tp249–59 and
Tp250–59 epitopes and it is notable that this residue is the
most frequently substituted in natural allelic variants of
the epitopes.27,35 The protrusion of the Lys56 residue side
chain above the pMHC I surface in models of both
Tp249–59/2*01201 and Tp250–59/2*01201 suggests that
regardless of their structural differences this is a critical
TCR contact residue for both epitopes. Consequently,
although this diversification strategy may confer some
benefit with regard to greater probability of eliciting
higher avidity T cells, the abrogation of both epitope-spe-
cific responses through a single substitution (of residue
Lys56) suggests the benefit to the host immune response
may be limited. Instead, the focusing of two CD8 T-cell
responses on a single, highly polymorphic peptide,27 both
of which are abrogated by the same single amino acid
substitution, could benefit the pathogen by augmenting
the strain-restricted nature of the T-cell response.
An initial objective in generating tetramers was to facil-
itate the tracking of epitope-specific CD8 T-cell responses
to T. parva in vivo. Tetramer-positive CD8 T cells were
detected for the most dominant epitopes following para-
site challenge of two previously immunized A10-homozy-
gous animals; cells positive for Tp249–59 were first
detected 9 days after challenge and reached peak levels
(up to 75% of the CD8 T cells) at 12–13 days. The mag-
nitude of these responses is similar to that reported
recently by Svitek et al.,29 who used tetramers to monitor
the Tp1214–224-specific responses in A18+ animals follow-
ing initial immunization with T. parva. The failure to
detect tetramer-positive cells ex vivo for the less dominant
epitopes in our study reflects limitations in the sensitivity
of the one-step staining method we employed, which
requires further refinement40 to improve sensitivity. The
kinetics of the responses to the dominant epitopes follow-
ing parasite challenge are similar to that observed in pre-
vious studies using limiting dilution analyses to monitor
CD8 T-cell responses to parasitized cells,39 although the
latter assay detected a much lower frequency of respond-
ing cells than tetramers. It is of note that Taracha et al.41
observed that the peak of the response detected by mea-
suring cytototoxicity occurs approximately 2 days earlier
compared with detection by limiting dilution analyses,
probably reflecting changes in the proportion of the
specific cells that express effector function over time.
These observations are consistent with evidence that tetra-
mers provide the most accurate means of quantifying epi-
tope-specific T cells.
In conclusion, our data have demonstrated that previ-
ously characterized bovine CD8 T-cell responses against
the Tp249–59 peptide sequence presented by 2*01201 are
ª 2016 The Authors. Immunology Published by John Wiley & Sons Ltd., Immunology12
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composed of non-cross-reactive T-cell subsets specific for
Tp249–59/2*01201 and Tp250–59/2*01201. Analysis of TRB
genes expressed by responding T cells and structural
modelling of the peptide–MHC complexes have shown
that these populations express distinct TCR repertoires
and that the Tp249–59/2*01201 and Tp250–59/2*01201
pMHC I complexes adopt different surface topographies
that account for lack of cross-reactivity of the respective
T-cell specificities.
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